Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.
Ifosfamide (IF) pharmacokinetics and the plasma (NBP)-alkylating activity were determined in 33 patients with different tumours after the administration of IF as single-agent chemotherapy. All subjects had been phenotyped for debrisoquine oxidation. There is a lack of correlation between the debrisoquine metabolic ratio (DMR) and either the total plasma clearance of IF (CLIF) or the AUC of the plasma NBP-alkylating activity.
Philip
P A
PA
Department of Clinical Pharmacology, United Medical School, Guy's Hospital, London Bridge, U.K.
Lewis
L D
LD
James
C A
CA
Rogers
H J
HJ
D000328:Adult; D000368:Aged; D000478:Alkylation; D003647:Debrisoquin / Q000378:metabolism*; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000493:pharmacokinetics*; D007546:Isoquinolines / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000378:metabolism; D010084:Oxidation-Reduction; D011110:Polymorphism, Genetic
D007546:Isoquinolines; D007069:Ifosfamide; D003647:Debrisoquin